retatrutide phase 2 weight loss results hits 28% in 3 retatrutide weight loss phase 2

(NASDAQ: WW) ("Weight Watchers"), the global leader in science-backed weight management, today introduced a new, fully integrated experience that unites GLP-1 prescribing, personalized nutrition, behavioral support, coaching, and community within a redesigned app experience and digital platform

At the time of writing, retatrutide is not FDA approved for weight loss or diabetes treatment in the United States

B12 adequacy is directly relevant here since B12 deficiency independently causes cognitive symptoms and mood disturbance, which is another reason the B12-containing formulation is preferred for long-term use

Training shifts the ratio of weight loss toward fat and away from lean mass